News >

Update Sustains Liso-Cel as Strong Contender in CAR T-Cell Space

Angelica Welch
Published: Thursday, Jun 14, 2018

Jeremy S. Abramson, MD, MMSc

Jeremy S. Abramson, MD, MMSc
The CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (JCAR017; liso-cel) is showing promising response rates in patients with high-risk diffuse large B-cell lymphoma (DLBCL).

during ASCO, lead investigator Jeremy S. Abramson, MD, MMSc, clinical director, Center for Lymphoma, Massachusetts General Hospital, discussed the latest data for liso-cel and its potential to become the third FDA-approved CD19-targeted CAR T-cell therapy.

OncLive: What is the background of the TRANSCEND trial?

Abramson: The TRANSCEND trial is a pivotal trial looking at the anti-CD19 CAR T-cell product JCAR017, now known as lisocabtagene maraleucel, in relapsed/refractory aggressive B-cell lymphomas. Liso-cel targets CD19 using a 4-1BB costimulatory domain, and signals CD3 zeta. We separated the CD4 and CD8 cells, then they were separately transduced and expanded, and then administered back to patients in a 1:1 ratio. What that results in is a fixed precise dose of CD4 and CD8 CAR-positive T cells administered to every patient. We began with a dose-finding component of the study, where we looked at 3 dose levels. [We evaluated] a single-dose level of 50 million cells administered at a single dose, a double-dose level of the same dose of 50 million cells administered 2 weeks apart, and then a dose level of 100 million cells as a single dose.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x